上海市锦天城律师事务所 关于重庆智翔金泰生物制药股份有限公司 实际控制人增持股份的 专项核查意见 地址：上海市浦东新区银城中路 501 号上海中心大厦 9、11、12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 专项核查意见 上海市锦天城律师事务所 上海市锦天城律师事务所（以下简称"本所"）接受重庆智翔金泰生物制药 股份有限公司（以下简称"智翔金泰"或"公司"）的委托，就公司实际控制人 蒋仁生先生增持智翔金泰股份事宜（以下简称"本次增持"）进行专项核查并出 具《上海市锦天城律师事务所关于重庆智翔金泰生物制药股份有限公司实际控制 人增持股份的专项核查意见》（以下简称"本专项核查意见"）。 本所及经办律师依据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司收购管理办法》 （以下简称"《收购管理办法》"）、《上海证券交易所上市公司自律监管指引第 8 号—股份变动管理》、《律师事务所从事证券法律业务管理办法》和《律师事务所 证券法律业务执业规则》等规定及本专项核查意见出具日以前已经发 ...

本报告中所指的投资及服务可能不适合个别客户，不构成客户私人咨询建议。在任何情况下，本报告中的信息或所表述的意见 均不构成对任何人的投资建议。在任何情况下，本公司、本公司员工或者关联机构不承诺投资者一定获利，不与投资者分享投 资收益，也不对任何人因使用本报告中的任何内容所引致的任何损失负任何责任。投资者务必注意，其据此做出的任何投资决 策与本公司、本公司员工或者关联机构无关。 本公司利用信息隔离墙控制内部一个或多个领域、部门或关联机构之间的信息流动。因此，投资者应注意，在法律许可的情 况下，本公司及其所属关联机构可能会持有报告中提到的公司所发行的证券或期权并进行证券或期权交易，也可能为这些公 司提供或者争取提供投资银行、财务顾问或者金融产品等相关服务。在法律许可的情况下，本公司的员工可能担任本报告所 提到的公司的董事。 市场有风险，投资需谨慎。投资者不应将本报告作为作出投资决策的唯一参考因素，亦不应认为本报告可以取代自己的判断。 在决定投资前，如有需要，投资者务必向专业人士咨询并谨慎决策。 本报告版权仅为本公司所有，未经书面许可，任何机构和个人不得以任何形式翻版、复制、发表或引用。如征得本公司同意进 行引用、刊 ...

证券代码：688443 证券简称：智翔金泰 公告编号：2024-016 重庆智翔金泰生物制药股份有限公司 关于参加 2023 年度科创板生物制品（二） 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2024 年 5 月 20 日(星期一)16:00 前通过邮件和电话形式将需 要了解和关注的问题提前提供给公司，公司将在文字互动环节对投资者普遍关注的 问题进行回答。 重庆智翔金泰生物制药股份有限公司（以下简称"公司"）已于 2024 年 4 月 3 日发布公司 2023 年度报告、2024 年第一季报告，为便于广大投资者更全面深入地 了解公司 2023 年度、2024 年第一季度经营成果、产品研发进展、发展战略等情况， 公司参与了由上交所主办的 2023 年度科创板生物制品（二）集体业绩说明会。此 次活动将采用网络文字互动的方式举行，投资者可登录上海证券交易所上证路演中 心（http://roadshow.sseinfo.com/）参与线上互动交流。 一、说明会类型 本次投资 ...

Investment Rating - The investment rating for the company is "Accumulate (Maintain)" [13][19]. Core Viewpoints - The company has made significant progress with multiple products, including the acceptance of the NDA for its core product, SecuMab, for moderate to severe plaque psoriasis, marking it as the first domestic submission for an anti-IL-17A monoclonal antibody [7][19]. - The company has a robust capacity and commercialization preparation, having completed the expansion of its antibody production base, which adds 20,000L of fermentation capacity for large-scale production of products like SecuMab and GR1802 [14]. - The company has 15 products in development, with 9 products approved for clinical trials across 17 indications, and expects substantial revenue growth from 2024 to 2026 [19]. Financial Performance Summary - The company reported a revenue of 1.21 million yuan in 2023, with R&D expenses increasing by 36.5% year-on-year to 620 million yuan [18]. - Revenue projections for 2024, 2025, and 2026 are 240 million yuan, 3.31 billion yuan, and 7.21 billion yuan respectively, indicating a significant growth trajectory [19]. - The net profit is projected to be -908 million yuan in 2024, improving to -730 million yuan in 2025 and -407 million yuan in 2026 [20].

GR1501为首个提交 NDA的国产 IL-17A单抗，商业化在即。2023年 3月，赛 立奇单抗注射液 NDA 获受理。2024 年 2 月，赛立奇单抗注射液针对中重度斑 块状银屑病 III 期临床研究结果在国际皮肤病学权威期刊 BJD上正式发表，数据 显示第 52 周 PASI75 应答率 96.5%，PASI90 应答率为 84.1%，PGA0/1 应答 率为 83.7%，表现出了优异且持久的疗效。复发的比例较低，用药第 52周复发 率为 0.4%，这表明 GR1501 可能具有更好的长期疗效。 盈利预测与投资建议。预计公司 2024-2026年实现营业收入分别约为 1.2、3.4、 7 亿元。考虑公司研发实力强劲，自身免疫疾病市场广阔，首款创新药 GR1801 获批在即，维持"买入"评级。 投资要点 西南证券研究发展中心 | --- | --- | |------------------------------------|------------| | | | | | | | | | | 基础数据 | | | [Table_BaseData] 总股本 ( 亿股 ) | 3.67 | | 流通 A 股 ...

智翔金泰-U（688443.SH） 增持 在研管线有序推进，赛立奇单抗获批在即 核心观点 公司研究·财报点评 相关研究报告 45 15 10 资料来源：公司公告、Wind、国信证券经济研究所整理 资料来源：公司公告、Wind、国信证券经济研究所整理 3) GR1603: 系统性红斑狼疮适应症处于 Ph2 临床试验阶段; 请务必阅读正文之后的免责声明及其项下所有内容 投资建议 请务必阅读正文之后的免责声明及其项下所有内容 财务预测与估值 免责声明 | --- | --- | --- | --- | |--------------------------------------------------------------------------------------------------|---------------|-------|----------------------------------------| | 投资评级标准 | 类别 | 级别 | 说明 | | 报告中投资建议所涉及的评级（如有）分为股票评 | | 买入 | 股价表现优于市场代表性指数 20%以上 | | 级和行业评级（另有说明 ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-----------------------------------------------|--------------------------------------|------------------------------------------------------------------|------------------|-----------------------------------------------------------|----------------------|------------|-----------------------------------------------------|---------------|-------------------| | [Table_MainInfo] [Table_Title] \n智翔金泰 | -U(688443) | | | | [Table_industryInfo] | | [Ta ...

R&D Investment and Development - The company's R&D investment for the reporting period was CNY 620.40 million, an increase of 36.50% compared to the same period last year, indicating a commitment to ongoing projects in clinical research [2]. - The company is focused on maintaining high levels of R&D investment as core products enter critical registration clinical phases, which may lead to sustained increases in R&D expenses [2]. - The company is actively developing multiple proprietary monoclonal antibodies and bispecific antibodies, enhancing its product pipeline [9]. - The company is focused on innovative drug development based on clinical needs, with an emphasis on new target drugs [41]. - The company has developed a technology platform for monoclonal antibody discovery based on a novel phage display system [44]. - The company has established two technology platforms for monoclonal antibody and bispecific antibody discovery based on a novel phage display system, enhancing its innovation capabilities [96]. - The company has optimized the phage display system to address issues in practical applications, resulting in two proprietary phage display antibody library technologies [97]. - The company has developed an efficient protein purification process platform based on Quality by Design (QbD) principles, enabling rapid development of purification processes for monoclonal and bispecific antibodies [99]. - Several innovative monoclonal and bispecific antibody drugs developed on the technology platforms have entered clinical research stages [107]. - The company has 15 products in the pipeline, with 9 products and 17 indications approved for clinical trials, and 2 indications' NDA accepted [185]. - The company has made significant progress in multiple products, overcoming challenges and seizing opportunities in 2023 [49]. Financial Performance - The net profit for 2023 was impacted by significant R&D expenditures due to multiple new drug products being in the research phase, leading to increased cash outflows from operating activities compared to the previous year [16]. - The company received government subsidies amounting to CNY 93.94 million, which significantly contributed to its financial performance [17]. - Non-operating income from financial investments generated a fair value gain of CNY 19.42 million, reflecting positive market conditions for the company's financial assets [17]. - The company's operating revenue for the current period is 1,211,502.42 million, a significant increase compared to 475,240.96 million in the same period last year, with a change ratio of not applicable [142]. - The company's net loss attributable to shareholders was -80,131.93 million, an increase in loss of 22,495.36 million compared to the previous year, mainly due to increased R&D expenditures [156]. - The net cash flow from operating activities was -377,580,702.25 million, worsening from -177,640,539.81 million in the previous year, mainly due to increased R&D investments [159]. - The net cash flow from investing activities was 120,620,808.83 million, up from 51,396,404.99 million, primarily due to the recovery of investments during the reporting period [159]. - The net cash flow from financing activities surged to 3,099,824,606.32 million, compared to 161,374,159.39 million in the previous year, largely due to funds raised from the initial public offering [159]. - The company's financial expenses decreased by 47.18% to 17,642,312.05 million from 33,397,889.23 million, attributed to interest income from raised funds [157]. Market Strategy and Expansion - The management has indicated a strategic focus on expanding market presence and exploring potential mergers and acquisitions to drive growth [18]. - The company aims to implement a clear market strategy and collaborate with established firms to accelerate new drug market penetration [34]. - The company is focused on the rapid growth of the biopharmaceutical market, particularly in the monoclonal antibody sector, which is expected to drive future development trends [63]. - The company plans to enhance operational management and internal controls to improve efficiency and profitability [151]. - The company is committed to maintaining a stable and continuous profit distribution policy to ensure reasonable returns for investors [131]. - The marketing team will utilize a four-pronged approach (market, medical, sales, and access) to accelerate the commercialization process [198]. Governance and Compliance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties, ensuring financial integrity [5]. - The company has ensured that all board members attended the board meeting, reflecting strong governance practices [3]. - The financial reports have been audited by a reputable accounting firm, ensuring the accuracy and reliability of the financial data presented [17]. - The company is committed to reducing and regulating related party transactions to enhance transparency and compliance [165]. - The controlling shareholder and actual controller have committed to avoiding competition with the company and its controlled enterprises, specifically regarding the CAR-T and CAR-NK drug pipelines, which are in clinical and preclinical stages [115]. Clinical Trials and Product Development - The Phase III clinical study of the company's monoclonal antibody, Salicic, for moderate to severe plaque psoriasis showed a PASI75 response rate of 90.7% at week 12, compared to 8.6% in the placebo group [23]. - The relapse rate for patients treated with Salicic at week 52 was only 0.4%, indicating potential long-term efficacy [23]. - The company is developing GR1802, a recombinant fully human anti-IFNAR1 monoclonal antibody, currently in Phase II clinical trials for systemic lupus erythematosus [24]. - The company has made significant investments in R&D, although specific figures are not provided in the extracted content [189]. - The company is currently in the III phase of clinical trials for GR1802, which targets multiple allergic conditions [170]. - The core product, Celeric monoclonal antibody injection, has 2 indications with NDA accepted, indicating imminent commercialization [198]. Risks and Challenges - The company acknowledges the risk of market promotion and sales not meeting expectations, particularly for its new products [138]. - The pharmaceutical industry is undergoing significant regulatory changes, which may adversely affect the company's operations if it fails to adapt its strategies accordingly [138]. - The company is focusing on therapeutic areas such as autoimmune diseases, infectious diseases, and oncology, but faces risks of being outcompeted by more innovative drugs in these fields [128]. - The company faces financial risks associated with the implementation of its equity incentive plan, which may affect its long-term development [127]. Share Repurchase and Stock Management - The company plans to repurchase shares, ensuring the repurchase price does not exceed the latest audited net asset value per share [80]. - The total amount used for share repurchase in a single accounting year shall not exceed 50% of the net profit attributable to the parent company's shareholders from the previous accounting year [80]. - The stock repurchase plan must be approved by the board and shareholders, requiring a two-thirds majority vote [120]. - The company will prioritize stock repurchase, followed by share purchases by the controlling shareholder and board members, to stabilize stock prices [119].

Financial Performance - The company's operating revenue for Q1 2024 was CNY 6,330.27 million, a significant decrease from CNY 100,013.67 million in Q1 2023[1] - The net loss for Q1 2024 was CNY 163,770.02 million, compared to a net loss of CNY 200,969.11 million in Q1 2023, indicating an improvement[1] - The diluted earnings per share for Q1 2024 was CNY -0.45, an improvement from CNY -0.73 in Q1 2023[3] - The net profit attributable to shareholders of the listed company was CNY -163,770,017.01, representing a decrease of 18.51% compared to the same period last year[21] - The basic earnings per share for the reporting period was CNY -0.45, a decrease of 38.36% year-over-year[21] Cash Flow and Expenses - The company's cash flow from operating activities showed a net outflow of CNY 144,561.28 million in Q1 2024, worsening from a net outflow of CNY 97,070.09 million in Q1 2023[3] - The net cash flow from operating activities was CNY -144,561,278.97, showing an increase of 48.92% compared to the previous year[21] - The company incurred financial expenses of CNY -6,310.97 million in Q1 2024, a notable change from CNY 8,728.43 million in Q1 2023[1] Research and Development - Research and development expenses totaled CNY 129,932.37 million in Q1 2024, down from CNY 146,474.84 million in the same period last year, reflecting a decrease of approximately 11.29%[1] - The company’s cash flow from operating activities increased due to expanded business scale and increased personnel costs, along with higher R&D investments compared to the previous year[39] Assets and Liabilities - Total assets at the end of Q1 2024 were CNY 3,451,396.30 million, down 3.98% from CNY 3,594,596.74 million at the end of the previous year[10] - The total current assets as of March 31, 2024, amounted to CNY 2,899,935,991.02, down from CNY 3,031,857,189.57 at the end of 2023[33] - The total liabilities and shareholders' equity amounted to CNY 3,451,396,299.56, a decrease from CNY 3,594,596,738.24[36] - Total liabilities were reported at CNY 792,604,233.69, down from CNY 810,364,379.85 in the previous period[48] - Current liabilities totaled CNY 120,052,848.55, a decrease from CNY 136,870,271.74 in the previous period[48] Equity and Retained Earnings - The company's total equity attributable to shareholders decreased by 4.51% to CNY 2,658,792.07 million compared to CNY 2,784,232.36 million at the end of the previous year[10] - Owner's equity totaled CNY 2,658,792,065.87, a decrease from CNY 2,784,232,358.39 in the previous period[48] - The company reported a net loss of CNY 1,784,294,412.96 in retained earnings, compared to a loss of CNY 1,620,524,395.95 in the previous period[48] Inventory and Cash Equivalents - Cash and cash equivalents at the end of Q1 2024 were CNY 2,758,128.02 million, a decrease from CNY 41,535.88 million at the end of Q1 2023[5] - The company’s inventory as of March 31, 2024, was CNY 59,886,569.94, compared to CNY 55,450,910.06 at the end of 2023[33] Government Subsidies and Non-Recurring Losses - The company received government subsidies amounting to CNY 769,104.22, which are closely related to its normal business operations[23] - The company reported a non-recurring loss of CNY 6,163.78 from the disposal of non-current assets, including the reversal of previously recognized asset impairment provisions[23] Other Information - The company has a long-term loan of CNY 608,455,615.86, consistent with the previous period[48] - Deferred income tax assets and liabilities were not applicable in this report[40] - The company has not disclosed any new product developments or market expansion strategies in this report[40]

(2) GR1802(IL-4R 靶点):中国进度较快的 IL-4R 靶向生物药之一,目前仅有 再生元和赛诺菲合作的度普利尤单抗获批上市;2023年12月,启动 GR1802 针对特 应性皮炎适应症的 III 期临床试验研究。 (3) GR1603 (IFNAR1 靶点):2023年1月,针对系统性红斑狼疮适应症的 I/II 期临床试验已完成。 (4) GR2002 (TSLP 双表位双抗靶点):2023年9月,哮喘适应症完成Ⅰ期临床 惑者招募工作;2023年12月,完成特应性皮炎的Ⅰ期首例患者招募工作。 感染性疾病类管线:产品竞争格局良好,管线进度较快 (1) GR1801 (RABV-G 靶点):中国进度较快的 RABV 双表位靶向双抗产品, 已于 2023年9月完成针对狂犬病被动免疫适应症 III 期临床的患者入组工作。 (2) GR2001 (TeNT 靶点): 已于 2023 年 3 月完成破伤风适应症的 I/II 期临床试 验首例患者入组工作。 肿瘤管线:基于 CD3 进行双抗药物的全面布局 (1) GR1803 (BCMA×CD3 双靶点): 于 2022年 5 月完成多发性骨髓瘤的Ⅰ期 临床试 ...